the vaccine – Page 136 – Communicable Diseases Research

In silico trial to test COVID-19 candidate vaccines: a case study with UISS platform

Research

Published on 2020-12-142022-10-27
Journal: BMC Bioinformatics [Category] COVID-19,

In silico trial to test COVID-19 candidate vaccines: a case study with UISS platform

Research

Published on 2020-12-142022-10-27
Journal: BMC Bioinformatics [Category] Coronavirus, COVID-19, Fulltext, MERS,

The role of manufacturers in the implementation of global traceability standards in the supply chain to combat vaccine counterfeiting and enhance safety monitoring

Article

Published on 2020-12-142022-10-29
Journal: Vaccine [Category] COVID-19,

Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models

Research Article

Published on 2020-12-102022-10-31
Journal: Emerging Microbes & Infections [Category] COVID-19, SARS,

[키워드] adjuvants Analysis animal model animal models biochemical analysis Biological characterized clinical trial confirmed case COVID-19 COVID-19 pandemic demonstrated develop DNase effective intervention effective vaccine Health humoral immune response IgG immune persistence immunization immunogenicity inactivated Inactivated vaccine investigated limit Neutralizing antibodies observation performed Phase I preclinical data preclinical study product proportion PROTECT reported Safe SARS-CoV-2 Seroconversion Seven shown Side effects Spread stimulated structural protein tested the disease the vaccine Toxicity Vaccine vaccine candidate virion Virology virus WHO Wuhan
[DOI] 10.1080/22221751.2020.1852059 PMC 바로가기 [Article Type] Research Article

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Clinical Trial

Published on 2020-12-102022-10-04
Journal: The New England Journal of Medicine [Category] MERS, SARS, 임상,

[키워드] 1:1 acute respiratory syndrome age assigned baseline BNT162b2 BNT162b2 mRNA BNT162b2 vaccine body-mass characterized conditions coronavirus coronavirus disease defined dose doses effective effective vaccine Efficacy ENCODE fatigue first dose full-length spike protein groups headache incidence Infection injection laboratory-confirmed median Mild-to-moderate nucleoside-modified RNA observer-blinded occurred of BNT162b2 Older Pain participant Placebo placebo recipient placebo-controlled prefusion primary end point randomization Randomly receive Result resulting Safety safety profile SARS-CoV-2 second dose Serious Adverse Event Sex subgroup the vaccine Trial two-dose regimen Vaccine Vaccines worldwide pandemic
[DOI] 10.1056/NEJMoa2034577 PMC 바로가기 [Article Type] Clinical Trial

Navigating the Quagmire: Comparison and Interpretation of COVID-19 Vaccine Phase 1/2 Clinical Trials

Review

Published on 2020-12-092022-10-28
Journal: Vaccines [Category] COVID-19,

COVID-19 vaccine race: watch your step for cancer patients

COVID-19 백신 경쟁: 암 환자의 발걸음을 조심하십시오

Comment

Published on 2020-12-072022-08-31
Journal: British Journal of Cancer [Category] MERS, SARS, 치료제,

Risk assessment and evaluation of China’s policy to prevent COVID-19 cases imported by plane

Research Article

Published on 2020-12-072022-10-28
Journal: PLoS Neglected Tropical Diseases [Category] COVID-19, MERS, SARS,

Quantifying the Impact of Public Perceptions on Vaccine Acceptance Using Behavioral Economics

Public Health

Published on 2020-12-032022-10-31
Journal: Frontiers in Public Health [Category] COVID-19, MERS, SARS,

COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology

Review

Published on 2020-12-022022-10-04
Journal: International immunopharmacology [Category] MERS, SARS, 유전자 메커니즘,

[키워드] ACE acute respiratory syndrome administration affecting albumin Alter assist association Cancer cancer patient Cancer patients caused condition contribute coronavirus Coronavirus disease 2019 COVID COVID-19 COVID-19 vaccine distribution effective effective vaccine Effective vaccines Efficacy exacerbated faster global pandemic highlighting immune system Immunocompromised immunocompromised individuals Immunocompromised patient implementation Interaction lack limitation Lipid nanoparticles mechanism mortality rate mRNA vaccine Nanomaterial Nanotechnology Neutrophils pandemic Patient personalised Pharmaceutics Prevalence required SARS-CoV-2 show the vaccine Treatment Vaccine Vaccine development vaccine platform viral spike protein viral strains Viral vector virus
[DOI] 10.1016/j.intimp.2020.107247 PMC 바로가기 [Article Type] Review